Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Release of Major Peanut Allergens from Their Matrix under Various pH and Simulated Saliva Conditions-Ara h2 and Ara h6 Are Readily Bio-Accessible.

Koppelman SJ, Smits M, Tomassen M, de Jong GAH, Baumert J, Taylor SL, Witkamp R, Veldman RJ, Pieters R, Wichers H.

Nutrients. 2018 Sep 11;10(9). pii: E1281. doi: 10.3390/nu10091281.

2.

Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.

van Lummel M, van Blitterswijk WJ, Vink SR, Veldman RJ, van der Valk MA, Schipper D, Dicheva BM, Eggermont AM, ten Hagen TL, Verheij M, Koning GA.

FASEB J. 2011 Jan;25(1):280-9. doi: 10.1096/fj.10-163709. Epub 2010 Sep 27.

PMID:
20876209
3.

AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency.

Vaessen SF, Veldman RJ, Comijn EM, Snapper J, Sierts JA, van den Oever K, Beattie SG, Twisk J, Kuivenhoven JA.

J Gene Med. 2009 Aug;11(8):697-707. doi: 10.1002/jgm.1344.

PMID:
19431216
4.

ABCA1-dependent but apoA-I-independent cholesterol efflux mediated by fatty acid-bile acid conjugates (FABACs).

Goldiner I, van der Velde AE, Vandenberghe KE, van Wijland MA, Halpern Z, Gilat T, Konikoff FM, Veldman RJ, Groen AK.

Biochem J. 2006 Jun 15;396(3):529-36.

5.

Enhanced conversion of triglyceride-rich lipoproteins and increased low-density lipoprotein removal in LPLS447X carriers.

Nierman MC, Prinsen BH, Rip J, Veldman RJ, Kuivenhoven JA, Kastelein JJ, de Sain-van der Velden MG, Stroes ES.

Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):2410-5. Epub 2005 Sep 29.

PMID:
16195478
6.

Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.

Veldman RJ, Koning GA, van Hell A, Zerp S, Vink SR, Storm G, Verheij M, van Blitterswijk WJ.

J Pharmacol Exp Ther. 2005 Nov;315(2):704-10. Epub 2005 Jul 22.

PMID:
16040815
7.

Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport.

te Vruchte D, Lloyd-Evans E, Veldman RJ, Neville DC, Dwek RA, Platt FM, van Blitterswijk WJ, Sillence DJ.

J Biol Chem. 2004 Jun 18;279(25):26167-75. Epub 2004 Apr 12.

8.

The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs.

Veldman RJ, Mita A, Cuvillier O, Garcia V, Klappe K, Medin JA, Campbell JD, Carpentier S, Kok JW, Levade T.

FASEB J. 2003 Jun;17(9):1144-6. Epub 2003 Apr 8.

PMID:
12692077
9.

Ceramide: second messenger or modulator of membrane structure and dynamics?

van Blitterswijk WJ, van der Luit AH, Veldman RJ, Verheij M, Borst J.

Biochem J. 2003 Jan 15;369(Pt 2):199-211. Review.

10.

Ara-C- and daunorubicin-induced recruitment of Lyn in sphingomyelinase-enriched membrane rafts.

Grazide S, Maestre N, Veldman RJ, Bezombes C, Maddens S, Levade T, Laurent G, Jaffr├ęzou JP.

FASEB J. 2002 Oct;16(12):1685-7. Epub 2002 Aug 21.

PMID:
12206990
11.

Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus.

Veldman RJ, Klappe K, Hinrichs J, Hummel I, van der Schaaf G, Sietsma H, Kok JW.

FASEB J. 2002 Jul;16(9):1111-3. Epub 2002 May 8.

PMID:
12039850

Supplemental Content

Loading ...
Support Center